LJUBLJANA, Slovenia, Dec. 23, 2025 (GLOBE NEWSWIRE) — Across the country, mountain resorts have further strengthened their facilities and services, introducing modern lift systems, comprehensive equipment hire, professional ski and snowboard schools and a wide range of guided experiences. This enables visitors of all levels to explore diverse winter activities, from high-energy alpine skiing, snowboarding […]

Slovenia Welcomes Winter with Expanded Snow Sports, Nordic Trails and Outdoor Adventures As winter takes hold, the Slovenian Tourist Board is spotlighting a rich and diverse winter sports season that goes far beyond traditional alpine skiing. With upgraded resort infrastructure, a unified Nordic experience and a broad range of outdoor activities, Slovenia is positioning itself

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX ) (MindMaze Therapeutics or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today outlined the evolution of its global reimbursement strategy to enable scalable patient access and sustainable commercial growth for next-generation neurotherapeutics. Building on

Seattle, Washington–(Newsfile Corp. – December 23, 2025) – KaJ Labs has announced a strategic expansion of its blockchain innovation roadmap through a multi-sector investment strategy aimed at supporting sustainable growth across the decentralized technology landscape. The initiative reflects KaJ Labs’ continued focus on advancing blockchain and artificial intelligence through structured research, ecosystem development, and long-term

(NASDAQ:REGN),(Paris:SAN),(NASDAQ:SNY), Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized Phase 3 trial, and

(NasdaqGM:VEON), Almaty, Dubai and Tokyo, December 23, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), and Rakuten Group, Inc. (TSE: 4755), announced today that Beeline Kazakhstan Holding, VEON's digital operator in Kazakhstan, and Rakuten Symphony, a subsidiary of Rakuten Group, have signed a Memorandum of Understanding (MoU) to explore strategic collaboration on next-generation

(Paris:SAN), Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) Dupixent is the first and only biologic medicine

VEON's Beeline Kazakhstan and Rakuten Symphony Collaborate to Advance Next-Generation Connectivity and Digital Infrastructure GlobeNewswire December 23, 2025 Almaty, Dubai and Tokyo, December 23, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), and Rakuten Group, Inc. (TSE: 4755), announced today that Beeline Kazakhstan Holding, VEON's digital operator in Kazakhstan, and Rakuten Symphony, a

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma GlobeNewswire December 23, 2025 Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by

Dupixent(R) (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma GlobeNewswire December 23, 2025 Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic